N-[(4-fluorophenyl)methyl]methanesulfonamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[(4-fluorophenyl)methyl]methanesulfonamide
• 化学式: C₈H₁₀FNO₂S
• mdl: MFCD01345415
• 分子量: 203.24
• InChiKey: HUEHZDVFQPKNFR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  54.6
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Thiamine analogues and their use as antibiotics
  申请人：Rheinische Friedrich-Wilhelms-Universität Bonn

  公开号：EP2626356A1

  公开（公告）日：2013-08-14

  The present invention relates to compounds according to general formula (I), pharmaceutical compositions comprising compounds according to general formula (I) and the use of the compounds for the treatment of a bacterial infection, particularly for use as an antibiotic.

  这项发明涉及符合一般式(I)的化合物，包括含有符合一般式(I)的化合物的药物组合物，以及利用这些化合物治疗细菌感染，特别是用作抗生素的用途。
• Sulfonamide compounds as cysteine protease inhibitors
  申请人：Woo Soon H.

  公开号：US20090233909A1

  公开（公告）日：2009-09-17

  The present invention is directed to compounds of formula (I) that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them. Wherein R3 is -alkylene-SO2NR5R6.

  本发明涉及式(I)的化合物，其为半胱氨酸蛋白酶的抑制剂，特别是对于B、K、L、F和S型的猫蛋白酶，因此可用于治疗这些蛋白酶介导的疾病。本发明涉及含有这些化合物的制药组合物以及制备这些化合物的过程。其中R3为-烷基-SO2NR5R6。
• NICOTINAMIDES AS JAK KINASE MODULATORS
  申请人：Portola Pharmaceuticals, Inc.

  公开号：EP2975027A1

  公开（公告）日：2016-01-20

  The present invention is directed to compounds of formula I and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition JAK kinase activity, methods ofinhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by JAK kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.

  本发明涉及作为 JAK 激酶抑制剂的式 I 化合物及其药学上可接受的盐、酯和原药。本发明还涉及用于制造此类化合物的中间体、此类化合物的制备方法、含有此类化合物的药物组合物、抑制 JAK 激酶活性的方法、抑制血小板聚集的方法，以及预防或治疗至少部分由 JAK 激酶活性介导的一些病症的方法，如不希望发生的血栓形成和非霍奇金淋巴瘤。
• SULFONAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS
  申请人：ViroBay, Inc.

  公开号：EP1819667B1

  公开（公告）日：2012-10-17
• US8163735B2
  申请人：——

  公开号：US8163735B2

  公开（公告）日：2012-04-24